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Loss of Id1 in the bone marrow (BM) severely impairs tumor angiogenesis resulting in significant inhibition of tumor growth.
This phenotype has been associated with the absence of circulating endothelial progenitor cells (EPCs) in the peripheral blood
of Id1 mutant mice. However, the manner in which Id1 loss in the BM controls EPC generation or mobilization is largely
unknown. Using genetically modified mouse models we demonstrate here that the generation of EPCs in the BM depends on
the ability of Id1 to restrain the expression of its target gene p21. Through a series of cellular and functional studies we show
that the increased myeloid commitment of BM stem cells and the absence of EPCs in Id1 knockout mice are associated with
elevated p21 expression. Genetic ablation of p21 rescues the EPC population in the Id1 null animals, re-establishing functional
BM-derived angiogenesis and restoring normal tumor growth. These results demonstrate that the restraint of p21 expression
by Id1 is one key element of its activity in facilitating the generation of EPCs in the BM and highlight the critical role these cells
play in tumor angiogenesis.
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INTRODUCTION
Bone marrow-derived hematopoietic and endothelial cells con-
tribute to tumor angiogenesis. Whereas hematopoietic cells
promote tumor angiogenesis in a paracrine manner by releasing
pro-angiogenic factors and creating permissive conditions in the
tumor microenvironment [1–4], EPCs are incorporated into
nascent blood vessels and differentiate into mature endothelial
cells [5–7]. In the past decade a number of reports have described
the incorporation of BM-derived EPCs into tumor vessels in both
spontaneous murine tumor models and human patients [6,7] but
the extent of incorporation and the functional importance of these
cells is still under intense debate. Our recent work has reconciled
some of these issues by showing that these cells are recruited to the
tumor site at very early stages of angiogenesis and are eventually
diluted or replaced by mature endothelial cells from the
neighboring vasculature. Ablation of these cells by radiolabeled
antibodies against an EPC-specific vascular endothelial-cadherin
(VE-Cadherin) epitope results in abnormal vasculature formation
and delayed tumor growth [8,9]. In addition, we recently
demonstrated that BM-derived EPCs play a critical role in
promoting vascular remodeling and tumor re-growth after
treatment with vascular disrupting agents [10]. This further
confirms the critical role of these cells at the very early stages of
tumor angiogenesis and underlines the importance of developing
effective strategies to inhibit the recruitment of these cells to the
tumor site and block their pro-angiogenic function. However, the
mechanisms that govern the behavior of these cells, from their
origin in the BM to their release into the circulation in response to
pro-angiogenic stimuli are still poorly understood.
Id1 is a member of a family of 4 proteins (Id1-4) known to
inhibit the activity of basic helix loop helix transcription factors by
restraining their ability to bind DNA [11,12]. Loss of Id1 in the
BM leads to a complete loss of the EPC population in the
peripheral blood, which has been correlated with a block in tumor
neovascularization and delayed tumor growth [5,10]. However,
the actual role of Id1 in regulating EPC formation or mobilization
remains unknown. We recently reported that the absence of Id1
compromises the self-renewing capacity of hematopoietic stem
cells (HSCs) in the BM, increasing their tendency to differentiate
towards the myeloid lineage. This functional defect is associated
with transcriptional changes in Id1 null HSCs, including the
increased expression of p21, a well-established target of Id1
repression [13]. Here we show that Id1 is required for the
previously described ability of phenotypic HSCs (Lineage- (Lin-)
cKit+Sca-1+ cells) [14] to give rise to endothelial progeny [15–17]
and demonstrate the opposing effects of Id1 and its target gene
p21 on endothelial and myeloid lineage differentiation in the HSC
subset. Ablation of p21 in the Id1-/- animals restores a functional
endothelial population, rescues the angiogenic defect observed in
the Id1-/- mice, and reverses the premature myeloid commitment
of Id1 null HSCs. These data describe for the first time a genetic
interaction between Id1 and p21 in regulating the genesis of EPCs
in the BM, thereby advancing our understanding of the biology of
these cells.
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Id1 expression is upregulated in BM progenitor cells,
during angiogenesis
Id1 expression is confined to the primitive progenitor cells (lineage
marker negative, or Lin- subset) in resting BM [13]. To identify
Id1-expressing cells in the BM upon a vascular endothelial growth
factor (VEGF) challenge, we injected mice with an adenovirus
encoding VEGF165 and an empty adenoviral control
(AdNull)(Figure 1). AdVEGF165 administration induces a dra-
matic upregulation of Id1 in a subset of cells comprising less than
0.5% of the total BM population. The Id1 positive cells were either
associated with the endosteal surface surrounding the BM
(Figure 1a left) or with the sinusoidal endothelium in the vascular
zone (Figure 1a right) both previously described as potential stem
cell niches [18–20]. The same pattern of Id1 expressing BM cells
was observed 4 days after tumor implantation (data not shown).
Quantitative real time PCR and western blot analysis confirmed
that Id1 is upregulated in BM progenitor cells in response to tumor
growth (Figures S1a and S1b) further demonstrating that
angiogenesis stimulates Id1 expression in a small subset of BM
progenitor cells.
Loss of Id1 impairs generation of EPCs in the BM
Id1-/- mice lack BM-derived circulating EPCs in the blood [5,10].
Whether this is due to a defect in the generation of endothelial
progenitors or to an inability of these cells to be released into the
circulation is still unknown. We therefore examined the EPC
population in the BM of wild type and Id1 mutant mice by
analyzing the expression of cell surface markers previously used to
detect blood circulating EPCs [10,17,21]. In wild type mice we
identified Lin- cells that expressed both the endothelial marker
Flk-1 and the progenitor marker c-Kit, representing about 0.2% of
Lin- cells (Figure 2a) These cells were also largely positive (.80%)
for VE-Cadherin, CD13 and AC133 (Figure 2b), characteristic
markers of immature endothelial cells [22]. Notably, the Lin- Flk-
1+ cKit+ population was severely depleted in the Id1-/- BM (less
than 0.06% compared to 0.2% in wild type p,0.001) (Figure 2a).
Consistent with a unique role in this cell subset, the level of Id1
mRNA in sorted Lin- Flk-1+ cKit+ cells is ,2 fold higher than in
uncommitted hematopoietic Lin-cKit+Sca-1+ (HSC) cells (fig 2d),
previously shown to be relatively enriched for Id1 expression and
functionally dependent on its activity [13]. To address the
alternative possibility that the described Id1–dependent Lin- c-
Kit+ Flk-1+ cells represent a previously uncharacterized subset of
pro-angiogenic myeloid progenitors, we measured the relative
expression of C/EBPa and PU.1, master regulators of granulocyte
and monocyte differentiation, respectively [23,24]. Both genes
were expressed at a low level, comparable to the expression in
uncommitted HSCs and inconsistent with a potential myeloid
identity of the Lin- c-Kit+ Flk-1+ cells (Figure S2).
We have recently shown that Lin- VE-Cadherin+ Flk-1+ BM-
derived cells differentiate into mature endothelial cells and
incorporate into a vascular network when co-cultured with mature
endothelial cells [9]. To assess in vivo whether Lin- c-Kit+ Flk-1+
BM cells have endothelial properties, we isolated this population
from animals expressing the green fluorescent protein (GFP). Four
hundred sorted cells were embedded into VEGF containing
matrigel and injected subcutaneously into recipient mice
(Figure 3a). Seven days post-implantation we observed VE-
cadherin expressing GFP+ cells integrated into the vessels
infiltrating the plug (Figure 3b). In addition, the number of
GFP+ cells in the plug was dramatically increased relatively to the
initial number of implanted cells, suggesting the ability of Lin-
Figure 1. Angiogensis induces upregulation of Id1 in BM progenitor cells. A) Immunohistochemical analysis of Id1 protein in femur sections from
mice treated with AdVEGF165 or with AdNull. Arrowheads indicate Id1-expressing cells in endosteal (left) and vascular (right) stem cell niche. Scale
bar 100 mm.
doi:10.1371/journal.pone.0001338.g001
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observations suggest that Lin- c-Kit+ Flk-1+ cells have properties
of endothelial cells in vivo and that their loss may contribute to the
defect in neo-angiogenesis described in the Id1 mutant mice.
Loss of Id1 impairs the endothelial differentation of
HSCs
The majority of Lin- cKit+ Flk-1+ cells do not express the stem cell
marker Sca-1 (Figure 2c) suggesting that these cells do not belong
to the pluripotent stem cell compartment [14] but rather could
represent their more restricted progeny. It is well established that
HSCs function as a source of endothelial cells in adult animals
[15–17], demonstrating that during adulthood as well as during
embryogenesis [25,26] endothelial and hematopoietic cells repre-
sent alternative differentiation fates of a common progenitor. Since
the absence of Id1 reduces the self-renewing capacity of the HSCs
by promoting their commitment toward the myeloid lineage [13]
we tested whether its absence could also reduce the multipotency
of HSCs and affect their ability to differentiate into functional
endothelial cells. To this end we purified Lin- cKit+ Sca-1+ HSCs
[14] depleted of Flk-1+ cells from wild type and Id1-/- BM and
used them to reconstitute lethally irradiated wild type and Id1-/-
mice (Figure 4). Four weeks post-transplantation we observed a
comparable number of circulating EPCs (defined as CD45- cKit+
CD13+ Flk-1+ cells [10,21]) in the blood of wild type and Id1-/-
recipient mice transplanted with wild type HSCs. In contrast,
Id1-/- HSCs completely failed to reconstitute the endothelial
Figure 2. Loss of Id1 impairs generation of EPCs in the BM. A) Flow cytometric analysis of the EPC fraction of BM cells from wild type (WT) or Id1-/-
mice. The profiles shown are representative of Lin- cells. The gates identified the Lin- c-kit+ Flk-1+ EPC population. The numbers indicate the average
percentage6SEM of c-kit+ Flk-1+ in the Lin- fraction (n=24, ***p,0.001). B–C) Flow cytometric analysis of the endothelial specific markers VE-
cadherin, CD13, AC133 (B) and the stem cell specific marker Sca-1(C) in the Lin- c-kit+ Flk-1+ population. The histograms represent the distribution of
Lin- c-kit+ Flk-1+ stained with the specific marker indicated (red) or the isotype control (blue). The numbers indicate the average percentage6SEM of
marker positive cells in the Lin- c-kit+ Flk-1+ fraction (n=5). D) Quantitative real time PCR analysis of Id1 mRNA levels in sorted HSCs and Lin-cKit+Flk-
1+ cells. The bars represent the fold change of Id1 mRNA levels in Lin-cKit+Flk-1+ cells relative to HSC levels. The results were normalized to HPRT
expression and expressed as average fold change6SD (Lin-cKit+Flk-1+ 2.760.69 n=4).
doi:10.1371/journal.pone.0001338.g002
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HSCs is necessary to allow endothelial differentiation. The ability
of wild type HSCs to reconstitute the EPC population in Id1-/-
mice provides a possible explanation for the restored tumor
angiogenesis previously observed in Id mutant mice after
transplantation with wild type BM [5,6,10].
Loss of Id1 does not affect the recruitment of pro-
angiogenic hematopoietic cells to the tumor site
A number of recent studies have emphasized the role of different
hematopoietic cells in promoting tumor growth and angiogenesis
[1–4]. Even though the analysis of BM-derived cells recruited into
the tumor stroma indicates that Id1 expression is confined to the
endothelial cells and is not detectable in other mature hemato-
poietic cells [6,27] it is possible that a defect in other BM-derived
cells contributes to the failure in angiogenesis observed in the Id1
mutant mice. In order to test this hypothesis we analyzed the
ability of Id1-/- mice to recruit pro-angiogenic hematopoietic cells
to growing tumors. Naldini and coworkers have identified a subset
of myeloid cells (the Tie2 expressing monocyte or TEM) that are
recruited to the tumor site and promote tumor angiogenesis in a
paracrine manner [4]. We analyzed the frequency of TEMs in
Id1-/- mice during tumor growth. Flow cytometry analysis showed
that Id1-/- mice have a normal number of TEMs, defined as
Tie2+ CD11b+ CD45+ cells [4] in both BM and peripheral blood
(Figure 5a and b). Moreover, we observed no difference between
wild type and Id1-/- mice in the recruitment of TEMs to the
stroma of implanted tumors (Figure 5c), demonstrating that loss of
Id1 does not affect the genesis, mobilization or function of Tie2
expressing monocytes. We also analyzed the infiltration of
macrophages and neutrophils into tumors grown in Id1-/- mice.
Using the tumor-associated macrophage marker CD68 [28]
(Figure 5d) and the neutrophil marker clone 7/4 [29] (Figure 5e)
we observed no difference between wild type and Id1-/- mice in
the number or localization of positive cells infiltrating the tumor.
Accelerated myeloid commitment of HSC cells in the
absence of Id1 requires the expression of its target
gene p21
The increased rate of myeloid commitment in the Id1-/- HSCs is
associated with higher expression of the known target of Id1
repression, the cyclin-dependent kinase inhibitor p21 [13].
Previous studies have revealed a role for p21 in regulating lineage
commitment of adult epidermal stem cells [30] and hematopoietic
Figure 3. Lin- cKit+Flk-1+ BM cells have endothelial properties. A) Schematic representation of thee x p e r i m e n t a lp r o c e d u r e .B )
Immunofluorescence on matrigel sections showing the incorporation of GFP+ Lin- c-kit+ Flk-1+ cells into vessels (arrowheads). Yellow and orange
insets show magnification of GFP+ cells. Green: GFP; Red: VE-Cadherin; Blue: DAPI. Scale bar 50 mm.
doi:10.1371/journal.pone.0001338.g003
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contribute to the altered cell fate determination of Id1 null HSCs
and restrict their potential to progress towards the endothelial
lineage. To test this hypothesis we generated Id1-/-p21-/- mice and
first analyzed whether ablation of p21 would counter the increased
myeloid commitment rate of the Id1-/- HSCs. Sorted HSCs (Lin-
cKit+ Sca1+ [14]) were cultured for 3 days in the presence of IL-3,
IL-6 and SCF to promote early myeloid differentiation. Whereas
Id1-/- HSCs showed accelerated expression of hematopoietic
lineage markers and loss of the stem cell specific marker Sca-1 (as
previouslyreported[13])theId1-/-p21-/-HSCsdisplayedanormal
rateofdifferentiation(Figure6a).Todistinguishbetweenaneffecton
cell differentiation versus proliferation, we stained sorted HSCs (Lin-
cKit+ Sca1+ [14]) with the vital dye CFSE [32] to track the
expression of lineage markers for each cell division. The Id1-/-
HSCs undergo more divisions, and within each generation show an
increased expression of the lineage markers compared to wild type
HSCs (Figure 6b). The ablation of p21 in Id1-/- HSCs completely
reverses the effects of Id1 loss on both the proliferation and
differentiation dynamics. In contrast, no significant effect of p21 loss
is observed in Id1 wild type cells, arguing against Id1–independent
effects of p21 deletion on cell cycle regulation in this assay.
Furthermore, the increased in vivo spleen colony formation by Id1
HSCs 8 days post-transplant (CFU-S8), characteristic of the
premature myelo-erythroid commitment [13], was also completely
corrected in Id1-/-p21-/- HSCs (Fig 6c).
As previously reported, Id1-/- HSCs have increased expression of
myeloid specific genesincluding the transcription factorc/EBPalpha
[13], a critical regulator of myeloid commitment in HSCs [33]. Loss
of p21 abolishes the upregulation of c/EBPa mRNA in the Id1-/-
HSCs (Figure 6c). This suggests that higher p21 levels could actually
promote myeloid differentiation of Id1-/-HSCs.
Ablation of p21 restores a normal Lin- Flk-1+ cKit+
population in the Id1 mutant mice
To assess whether ablation of p21 can also restore the angiogenic
potential of Id1-/- BM cells, we analyzed the frequency of Lin-
Flk-1+ cKit+ by flow cytometry in wild type, Id1-/-, p21-/- and
Id1-/- p21-/- mice (Figure 7a). The severe deficiency of these cells
observed in the Id1-/- mice was nearly completely corrected in the
Id1-/- p21-/- mice. Furthermore we detected a comparable
number of circulating EPCs [10,21] in the blood of wild-type and
Id1-/-p21-/- double mutant mice (Figure 7b), while almost none
were detectable in the blood of Id1-/- mice, as previously reported
[10]. Moreover, flow cytometric analysis of tumor tissue showed a
comparable number of infiltrating CD11b- VE-Cadherin+ cells in
wild type and Id1-/-p21-/- mice (data not shown). To demon-
strate that ablation of p21 rescues the ability of Id1-/- HSCs to
generate the endothelial population we transplanted 4 groups of
sublethally irradiated Id1-/- mice with 20 highly purified long
term repopulating HSCs (defined as Lin- cKit+ Sca1+ and CD34-)
[34] depleted of any Flk-1+ cells, isolated by flow cytometry from
wild type, Id1-/-, Id1-/-p21-/- and p21-/- mice. Four weeks after
transplantation we analyzed the frequency of circulating EPCs by
flow cytometry. While no EPCs were detected in the blood of
Id1-/- mice transplanted with Id1-/- HSCs, the Id1-/-p21-/-
HSCs generated endothelial progeny in the blood of the recipient
mice. The frequency of HSC-derived circulating EPCs was
significantly lower in the recipients of both p21-/- and Id1-/-
p21-/- than wild-type HSCs, indicating additional, Id1-indepen-
dent effects of p21 loss on circulating EPC differentiation and/or
homeostasis. (Figure S3.)
To demonstrate that the Id1-/- p21-/- Lin- Flk-1+ cKit+ cells
were functionally able to sustain tumor angiogenesis we analyzed
the rate of tumor growth in the Id1-/- p21-/- mice. 2610
6 Lewis
Lung Carcinoma (LLC) tumor cells were injected subcutaneously
into wild type, Id1-/-, p21-/- and Id1-/-p21-/- mice and tumor
growth followed for 12 days (Figure 7c). As previously reported
[5,35], Id1-/- mice showed a slower rate of tumor growth
compared to wild type mice (80% less growth seen 7 days after
implantation p,0.001). However, a similar tumor growth rate was
observed in wild type, p21-/- and Id1-/- p21-/- mice throughout
the duration of the experiment. Since slower tumor growth in the
Id1 mutant mice has been associated with decreased density and
abnormal structure of the vasculature [35], we analyzed the
vascular organization of the LLC tumors grown in the four
different groups of mice (Figure 7d and Figure S4). Staining for
VE-cadherin expression showed a homogeneous density of large
vessels and small capillaries invading the stroma of tumors grown
in wild type mice. As expected, tumors grown in the Id1-/- mice
displayed a significant decrease in the number and size of the
vessels. In accordance with the restored tumor growth observed in
the Id1-/- p21-/- mice, the tumors taken from these animals
showed a normal vascular density. Moreover, transplantation of
Id1-/- p21-/- BM into Id1 mutant mice rescued normal tumor
growth (data not shown) further confirming that the correction of
the angiogenic phenotype observed in the double mutant mice is
due to the effects in the BM compartment and not to effects on
other peripheral components of the tumor stroma. Overall these
observations support the hypothesis that the defect in BM-derived
tumor angiogenesis described in the Id1 mutant mice is due
primarily to a differentiation failure within the endothelial lineage.
However, we cannot exclude the possibility that normalization of
other BM populations might also contribute to the rescue observed
in the Id1/p21 double mutant mice.
DISCUSSION
It has been known for several years that depletion of the dominant
negative helix-loop-helix protein Id1 in mice leads to a failure of
tumor angiogenesis and consequently a significant delay in tumor
growth [5,10]. While a role for Id1 in the non-BM derived
endothelial cell component of some tumors has been established
[6], in other settings it is clear that the phenotype observed in the
Id1-/- mice is due to a failure in the BM compartment since
normal tumor angiogenesis can be completely rescued by
transplantation with wild type BM [5,6,10]. We have previously
shown that loss of Id1 leads to the absence of BM-derived blood
Figure 4. Id1 is necessary for the endothelial differentiation of BM
stem cells. Flow cytometric analysis of EPCs in the peripheral blood of
the indicated mice 4 weeks after transplantation of Lin- cKit+ Sca-1+
Flk-1- HSCs. The bars represent the average number or circulating EPCs
(6SEM). per ml of blood. WT+WT HSCs: 0.10560.002 (n=3); WT+Id1-/-
HSCs: 0.00960.009 (n=3); Id1-/-+WT HSCs: 0.07760.034 (n=4); Id1-/-
+Id1-/- HSCs: 0.00260.008 (n=4).
doi:10.1371/journal.pone.0001338.g004
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stimulation [5–10]. Two general models, not necessarily mutually
exclusive, could be imagined: progenitor cells are formed in the
BM but fail to migrate out into the blood circulation or the cells
fail to form in the first place. The experiments described here
demonstrate that in Id1 mutant BM there is profound reduction in
a population of cells (Lin- Flk-1+ cKit+) that have properties of
EPCs. This population expresses characteristic progenitor cell
markers (i.e. Lin-, ckit+ AC133 +) and endothelial cell markers
(VEGFR2+, VE-Cadherin+, CD13+) (Figure 2) and has a pattern
of gene expression different from myeloid cells (Figure 2 and
Figure S2). In addition, when purified these cells have the ability to
respond in vivo to VEGF and become incorporated into mature
vessels (Figure 3). In humans, the stem cell markers CD34 and
CD133 have been used together to identify endothelial progenitor
cells in clinical samples but cannot be used in the mouse owing to
the lack of CD34 expression on EPCs [22]. While we cannot rule
out the possibility that in the mouse other BM cell types are
affected by loss of Id1, our results argue strongly that the absence
of the endothelial progenitor population defined here is a critical
component of the angiogenic defect observed in the Id1-/- mice.
Indeed we show that while the Lin- Flk-1+ cKit+ population is
Figure 5. Loss of Id1 does not affect function of pro-angiogenic myeloid cells. Flow cytometry analysis of the TEMs in BM (A) peripheral blood (B)
and LLC tumor (C) of wild type (wt) or Id1-/- mice. The plots represent the percentage of Tie2+ CD45+ Cd11b+ of nucleated cells in wild type and
Id1-/- mice. Average6SEM: BM WT=2.6460.27 n=9; Id1-/-=2.560.17 n=12. Peripheral blood WT=2.160.21 n=14; Id1-/-=3.1460.28 n=14. Tumor
WT=260.27; Id1-/-=1.4460.16. D) Anti-CD68 immunofluorescence on LLC tumor sections showing infiltration of TAMs in WT and Id1-/- mice. Scale
bar 50 mm. E) Anti-neutrophils antibody clone 7/4 immunofluorescence on LLC tumor sections showing infiltration of neutrophils in WT and Id1-/-
mice. Scale bar 100 mm. F–G) Quantification of immunofluorescences shown in D and E. The histograms represent the number of positive cells
counted per field (magnification 630X) in LLC tumors collected from WT and Id1-/- mice. A minimum of 6 non sequential sections were counted. TAM
average6SEM (20.8663.6 WT 23.6764.5 Id1-/-) Neutrophils average6SEM (9.261.1 WT 10.761.2 Id1-/-).
doi:10.1371/journal.pone.0001338.g005
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hematopoietic cell types (Tie2 expressing monocytes, tumor
associated macrophages and neutrophils) are normal in the
absence of Id1 (Figure 5). Moreover, restoration of Lin- Flk-1+
cKit+ cells in the BM by genetic manipulation (see below) leads to
a complete reversal of the Id1 null defective vascular phenotype.
How does Id1 control the formation of these cells in the BM?
We have reported previously that the loss of Id1 leads to the
premature commitment of hematopoietic stem cells to the myeloid
lineage [13] and we demonstrate here that this loss also affects the
formation of the endothelial population (Figure 4). Several studies
in the past decade have demonstrated that adult HSCs can give
rise to functional endothelial cells [15–17] and we now
demonstrate that Id1 expression is critical for this process.
Upregulation of the cyclin dependent kinase inhibitor p21 as a
result of Id1 loss is associated with enhanced cycling of the stem
cell population, accelerated expression of myeloid markers and loss
of EPCs. Ablation of p21 in the Id1 mutant background (through
genetic manipulation) completely corrects the differentiation defect
of HSCs restoring a normal EPC population in the BM and in the
peripheral blood and rescuing normal tumor angiogenesis (Figure 6
and 7). Under steady-state conditions the expression of p21 is
enriched in HSCs relative to committed hematopoietic progenitors
[36], maintaining the stem cell self-renewal capacity perhaps by
regulating their cell cycle entry [37]. Despite its growth inhibitory
function in HSCs, several studies have demonstrated a positive
effect of p21 induction on growth and differentiation in transiently
amplifying myeloid progenitors [38,39]. Consistent with this, the
proliferation and differentiation of G-CSF mobilized murine
HSCs is associated with a relative induction of p21 [40], indicating
a possible positive role in the HSC differentiation program. We
propose that increased p21 levels in the absence of Id1 could act
similarly and support the increased myeloid lineage commitment
of Id1-/- HSCs. Although further study is required to dissect the
molecular mechanisms by which Id1 and p21 regulate HSC
commitment, we suppose that upregulation of p21 (induced by loss
of Id1) not only primes HSCs toward the myeloid fate but that
premature priming may deplete the endothelial progenitor cell
Figure 6. The increased myeloid priming of Id1 null HSCs requires the expression of p21. A–B) In vitro differentiation of sorted HSCs in response to
cytokine stimulation. We monitored the acquisition of hematopoietic lineage markers and the simultaneous loss of expression of Sca-1 (A). The
numbers represent the percentage of Lin
low Sca-1
+ cells remaining after 3 days in culture. The coupling of lineage differentiation with proliferation
was analyzed by the progressive decrease in CFSE staining intensity with each cell division (B). The arrows correspond to each subsequent division,
and the numbers represent the fraction of differentiated (Lin
+) cells within each generation. The shown data is representative of three independent
experiments. (C) Spleen colony forming assay using sorted Id1-/- HSCs cells. 500 sorted HSCs from the indicated groups of mice were transplanted
into lethally irradiated recipients, and spleen colonies were scored on day 8 post-transplant. Numbers indicate average colony numbers6SEM (WT
1.560.64 n=4; Id1-/- 3.860.58 n=5; Id1-/-p21-/- 0.560.28 n=4; p21-/- 160.40 n=4) D) Quantitative real time PCR analysis of c/EBPa mRNA levels in
sorted HSCs. The bars represent the fold change of c/EBPa mRNA levels in Id1-/-, Id1-/-p21-/- and p21-/- mice relative to WT levels. The results were
normalized to HPRT expression and expressed as average fold change6SD (Id1-/- 2.660.7; Id1-/- p21-/- 0.7160.22; p21-/- 0.8560.53 n=2).
doi:10.1371/journal.pone.0001338.g006
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of EPCs, p21 may act as a tumor suppressor by both inhibiting
tumor angiogenesis (by repressing EPCs formation in the BM) as
well as by restraining tumor cell proliferation directly.
The upregulation of p21 in response to Id1 loss may be a direct or
indirect consequence of the liberation of E proteins. Indeed, in
fibroblasts overexpression of E proteins leads to the direct activation
of the p21 promoter [41] but in HSCs the situation may be more
complex.It isalso notyet clearhowp21 upregulation,intheabsence
of Id1, leads to the coordinated skewing of gene expression towards
that of the myeloid lineage. Nevertheless, the observed effect of p21
induction isnot consistentwith itscanonical cellcycle inhibitoryrole,
ascultured Id1nullHSCs undergo moreproliferation thanwild type
cells, perhaps due to the pro-proliferative activity of p21 that has
been reported in other systems [42].
As has been pointed out previously [43] it is unlikely that the Id
proteins are ‘‘hard-wired’’ to drive the progression of the cell cycle
as Id1, 2, 3 triple knockout embryos undergo many rounds of cell
division prior to embryonic lethality, suggesting an effect on cell
fate which may in some cases impinge on cell cycle progression. In
fact, loss of Id1 leads to enhanced proliferation of HSCs both in
vitro as well as in vivo [13]. However, proliferation per se is not the
sole reason for the altered differentiation profile in the Id1
knockout cells since vital dye marking of the HSCs, which allows
for marker analysis at each cell division, shows a clear change in
differentiation status at each cell division.
The extent of utilization of BM derived endothelial cells has been
shown to vary with tumor type and tumor grade [6,7]. Even under
circumstances where low incorporation of these cells is observed,
their importance has been supported by bone marrow transplantion
studies using the Id1 mutant model in which the EPC function is
completely impaired [5,6,10]. We have shown recently that
utilization of EPCs is most prominent early in tumor development
and that antibodyablationspecificallyoftheEPCpopulation mimics
the phenotype described in the Id1-/-mice with abnormal tumor
vasculature and delayed tumor growth [8,9]. Other BM derived cell
types have also been shown to be important in the neoangiogenesis
process [1–4] however, the relative contribution of each remains a
subject of intense debate. While this issue is not resolved fully by
these studies, our work supports the idea that Id1-expressing BM-
derived EPCs are a critical component of tumor neovascularization:
Id1 is required for normal tumor angiogenesis, Id1 expression in
HSCs is required for the generation of progenitor cells with the
ability to become incorporated into blood vessels, Id1 is only
Figure 7. Loss of p21 rescues functional BM-derived tumor angiogenesis in Id1-/- mice. A) Flow cytometric analysis of the EPC fraction of BM cells
from wild type; Id1-/-; Id1-/- p21-/- and p21-/- mice. The plots represent the percentage of cKit+ Flk-1+ cells in the population of Lin- BM cells in the
indicated groups of mice. Average6SEM : wt=0.2560.03 (n=8); Id1-/-=0.05460.009 (n=6); Id1-/- p21-/-=0.260.018 (n=7); p21-/-=0.1760.02
(n=7). p=0.0007 ***, p=0.0012 ** B) Flow cytometry analysis of the circulating EPC fraction in the peripheral blood of wt; Id1-/-; Id1-/- p21-/- and
p21-/- mice. The plots represent the number of CD45-cKit+ Flk-1+ CD13+ cells per ml of blood in the different groups of mice. Average6SEM:
wt=0.3160.04 (n=8); Id1-/-=0.02460.01 (n=8); Id1-/- p21-/-=0.3860.042 (n=6); p21-/-=0.3560.09 (n=3). p,0.001 *** C) Growth curve of LLC
tumors implanted into wild type; Id1-/-; Id1-/- p21-/- and p21-/- mice. D) VE-cadherin immunofluorescence on tumor sections showing the vascular
density in the indicated genotypes. Scale bar 100 mm.
doi:10.1371/journal.pone.0001338.g007
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pericytes [6], and Id1 loss does not affect the levels of monocytes,
macrophages or neutrophils in the peripheral blood or at the site of
the tumor (Figure 5).
In conclusion, this work describes for the first time the opposing
activity of two regulators of the differentiation of BM-derived
EPCs from BM stem cells, Id1 and p21, and supports the
importance of these cells during tumor angiogenesis. Further
studies will be required to fully characterize the regulatory
mechanisms that govern the function of these cells and therefore
to design functional strategies to inhibit their activity.
MATERIALS AND METHODS
Animal and tumor models
All studies were conducted using age matched (8–10 week old)
C57B6/Sv129 mice. Actin-GFP transgenic mice C57BL/6-
Tg(ACTbEGFP)10sb/J were purchased from The Jackson
Laboratory (Bar Harbor, Maine). The animals were maintained
in pressurized ventilated caging at MSKCC according to IACUC
approved protocol. Lewis Lung Carcinoma cells (LLC) (ATCC,
Manassas, VA) were cultured in DMEM supplemented with 10%
FBS. For tumor growth experiments, 2610
6 LLC cells were injected
subcutaneously into recipient mice. Tumor size was assessed every
two days using a Venier caliper. After 14 days, tumors were
surgically removed and analyzed by immunofluorescence. The
AdVEGF165 and AdNull vectors were previously described [5] and
obtained from Dr. Ronald Crystal. Mice were injected intravenously
with 1.5610
8 particle forming units (pfu) of AdVEGF165 and
AdNull. 48 hours after injection the animals were sacrificed and
femurs collected for histological analysis. For the BM transplantation
experiments, age matched wild type and Id1-/- mice were lethally
irradiated (10 Gy) and reconstituted with 5000 sorted Lin- cKit+
Sca-1+ Flk-1- HSCs, along with 5610
5 syngenic Id1-/- total BM
mononuclear cells. The Flk-1- HSCs mice used for transplantation
were sorted as described below, from age matched wild type and
Id1-/- mice. For the matrigel experiments, GFP+Lin- cKit+ Flk-1+
BM-EPCs were sorted as described below. 400 sorted cells were
resuspended in 400 ml of grow factor reduced matrigel (BD
Bioscences) supplemented with 400ng/ml of mouse VEGF (Pepro-
tech, NJ) and injected subcutaneously into recipient mice. Seven
daysafter implantation the matrigel plug was removed and prepared
for histological analysis, as described below.
Immunohystochemistry and Immunofluorescence
Femurs were fixed in 10% formalin for 24 hours, decalcified in
EDTA/Formalin for additional 24 hours embedded into paraffin
and sectioned. 5 mm sections were stained with a rabbit
monoclonal antibody against mouse Id1 [27], using the ABC kit
(Vector Laboratories) according to the manufacturer’s instruction.
Tumors and matrigel plugs were removed and immediately
embedded in Optimal Cutting Temperature (O.C.T.) compound
(Sakura Finetek, CA). 8 mm sections were stained with rat anti-
VE-cadherin (BD Pharmingen), rat anti-CD68 [28] and rat anti-
neutrophil clone 7/4 [29] (Serotec) followed by staining with Alexa
546-conjugated goat anti-rat antibody (Molecular Probe). Images
were captured using an Axiovert 200 microscope (Zeiss).
Antibodies and Flow Cytometry
For flow cytometry analysis and sorting, we used the following
antibodies: Biotin conjugated anti mouse lineage cocktail (con-
taining CD3, CD4, CD5, CD8, B220, Gr1, CD11b, Ter119
antibodies), PercP conjugated anti Streptavidin, APC-Cy7-
conjugated anti Streptavidin, APC-conjugated anti c-Kit, PE-
conjugated anti Flk-1, Sca-1 and CD45, FITC-conjugated anti
CD13, Sca-1 and Cd11b, PerCP conjugated CD45 PerCP Alexa
647-conjugated VE-cadherin (BD Pharmingen); FITC-conjugated
AC133 and PE-conjugated Tie2 (e-Bioscence, CA); 7AAD
(Calbiochem). BM cells were collected from femurs and tibiae in
X-VIVO 20 media (Cambrex, CA) for analysis and sorting and
stained with the indicated combination of antibody. Flow cytometry
analysis of blood circulating EPCs was carried out as previously
described [10,23] , as was the analysis ofTEMs inthe BMand blood
reported [4]. Tumors were digested at 37uC for 45–60 min with an
enzyme cocktail (Collagenase A, elastase, and DNase I, Roche
Applied Science) and filtered through a 30-um strainer. A single cell
suspension was stained to identify TEMs as previously report [4].
Flow cytometry analysis was performed using the FACSCalibur
cytometer (Becton Dickinson, CA). Flow cytometry sorting was
performed using the MoFlo cell sorter from Cytomation, (Fort
Collins, CO). All flow cytometry data were analyzed using FloJo
software package (Tree Star, Mountain View, CA).
Analysis of in vitro HSC myeloid differentiation
HSCs were sorted by flow-cytometry as described above. Sorted
cells were seeded at a density of 5000cells/well in the non-tissue
culture treated 12-well plates (BD Falcon, CA), with 1 ml of
culture media. For all in vitro culture we used X-vivo 15 serum-free
media (Cambrex, CA), supplemented with 55 mM 2-mercapto-
ethanol (Invitrogen) and a cocktail of early-acting myeloid
supporting cytokines 2100 ng/ml SCF , 10 ng/ml IL-3 and
10 ng/ml IL-6 (Peprotech, NJ). For the in vitro differentiation
assays, cells were analyzed for lineage markers and Sca-1
expression by flow-cytometry following 72h of culture. For the
in vitro cell division tracking experiments, cells were labeled with a
vital dye CFSE (carboxyfluoroscein succinimidyl ester) (Molecular
Probes) prior to seeding, as previously described [32]. Following
72 h of culture, cells were simultaneously analyzed for lineage
marker expression and CFSE fluorescence. The discrete peaks of
CFSE fluorescence corresponding to the individual generations of
divided cells, were determined using the proliferation analysis
module of the FloJo software package (Tree Star, Mountain View,
CA). For the in vivo spleen colony forming assay, lethally
irradiated recipients were transplanted with 500 sorted Lin- cKit+
Sca1+ cells/mouse. Transplant recipients were sacrificed and
macroscopic spleen colonies were scored 8 days post-transplant.
Quantitative Real Time PCR
BM Lin- progenitors and HSCs used for qRT-PCR were sorted as
described above. Total RNA was collected using RNAeasy kit
(QIAGEN, CA), (for HSCs only) amplified using Gene Chip Two-
Cycle cDNA Synthesis (Affimetryx, CA) and retrotranscribed
using ThermoScript RT-PCR System (Invitrogen). Quantitative
PCR was carried out using the SYBR green PCR Mastermix
(Applied Biosystems) and the 7900 Real Time PCR system
(Apllied Biosystems). Relative expression of target genes was
calculated using standard curve method and normalized to HPRT
mRNA content. Primers used: Id1 Forward 59-CGA CTA CAT
CAG GGA CCT GCA-39 Id1 Reverse 59-GAA CAC ATG CCG
CCT CGG-39; cEBP alpha Forward 59-GAT CTG CGA GCA
CGA GAC-39 cEBP alpha Reverse 59-CTT GGC CTT CTC
CTG CTG-39.
SUPPORTING INFORMATION
Figure S1 Id1 is upregulated in Lin- progenitor cells upon pro-
angiogenic stimuli. A) Quantitative real time PCR analysis of Id1
mRNA levels in Lin- sorted BM cells from wild type mice
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PLoS ONE | www.plosone.org 9 December 2007 | Issue 12 | e1338untreated or 4 days after LLC tumor implantation. The bars
represent fold induction of Id1 mRNA levels in sorted Lin- cells
upon tumor implantation relative to steady state levels. The results
were normalized to HPRT expression and expressed as average
fold induction6SD (4.8460.45; n=3). B) Western blot analysis of
Id1 protein (upper panel) and actin (lower panel) in sorted Lin-
cells from wild type mice untreated or 4 days after LLC tumor
implantation.
Found at: doi:10.1371/journal.pone.0001338.s001 (0.15 MB TIF)
Figure S2 Lin- cKit+ Flk-1+ cells do not show higher expression
of myeloid determining genes compared to incommitted HSCs.
Quantitative real time PCR analysis of c/EBPa (A) and PU.1 (B)
mRNA levels in sorted HSCs and Lin-cKit+Flk-1+ cells. The bars
represent the fold change of c/EBPa and PU.1 mRNA levels in
Lin-cKit+Flk-1+ cells relative to HSC levels. The results were
normalized to HPRT expression and expressed as average fold
change6SD (c/EBPa 1.360.17 n=6; PU.1 1.360.147 n=6).
Found at: doi:10.1371/journal.pone.0001338.s002 (0.26 MB TIF)
Figure S3 Ablation of p21 rescues the endothelial differentiation
defect of Id1-/- HSCs. Id1-/- mice were sublethally irradiated
then transplanted with 20 Lin- cKit+ Sca-1+ CD34- Flk-1- HSCs
purified from the BM of the indicated group of mice. The
histograms represent the flow cytometry analysis of circulating
EPCs in the peripheral blood of Id1-/- mice 4 weeks after
transplantation. The bars represent the average number or
circulating EPCs (6SEM) per ml of blood. WT HSCs:
0.460.007 (n=5); Id1-/- HSCs: 0.000160.0003 (n=3); Id1-/-
p21-/- HSCs: 0.06
Found at: doi:10.1371/journal.pone.0001338.s003 (0.13 MB TIF)
Figure S4 Quantification of vessels in LLC tumors from WT,
Id1-/-, Id1-/-p21-/- and p21-/- mice. A minimum 400 vessels
were counted from 5 non sequential sections were counted.
Average6SEM: WT 5168.8; Id1-/- 14.5661.9; Id1-/-p21-/-
48.7865.7 and p21-/- 41.8963.55.
Found at: doi:10.1371/journal.pone.0001338.s004 (0.12 MB TIF)
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